Prescient Therapeutics Ltd (AX:PTX) is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations into FY19. We value Prescient at A$62m or A$0.29 per share.
PTX-100 to target RhoA-mutant lymphomas
Prescient has announced that it will resume clinical development of its second anti-cancer drug, PTX-100, in rare lymphomas where mutations of RhoA are common, such as angio-immunoblastic T-cell lymphoma. PTX-100 blocks an essential step in the activation of many downstream signalling proteins in the Ras oncogene signalling pathway, including RhoA. Clinical studies in this indication are expected to commence in mid-2018, after preclinical studies to confirm the mechanism of action of PTX-100 in RhoA mutant tumours are completed. The smaller trial sizes and potential for accelerated approval in this niche indication mean that Prescient could potentially conduct a pivotal study itself before seeking to out-license.
To read the entire report Please click on the pdf File Below: